NEW YORK, Feb. 13 /PRNewswire/ -- Today, more than ever before, pharmaceutical sales and marketing executives are facing challenges from all sides. Internally, the pressure to fill pipelines, demands for more R&D results, and competition from generics demand new outcomes from pharmaceutical marketing and sales teams across the board.
Externally, new U.S.-based regulatory (e.g. post-approval monitoring), legislative, and patent issues continue to loom. Changes affecting the sales and marketing functions of the industry are inevitable as a new administration takes control of the FDA, FTC and other agencies in 2009.
International Institute for Business Information & Growth (iiBIG)
presents the 2nd Annual Pharmaceutical Sales & Marketing Executive
Congress, scheduled for March 31 - April 1, 2008 in Bethesda, Maryland.
This year's conference will outline trends, case studies, and
best-practices required to reformulate pharmaceutical marketing and sales
strategies in the light of the new rules of engagement. Two new speakers to
join our speaking faculty are:
-- Adriane Fugh-Berman MD, Associate Professor, Complementary and
Alternative Medicine Masters Program, Department of Physiology and
Biophysics, Georgetown University
Dr. Fugh-Berman will discuss important developments from the physician side and how physicians are responding to some irregular and wrong practices in pharma CME.
-- Lori Ryan, Executive Director, Head of Finance CVM Sales Force,
Ms. Ryan joins our panel on the State of the Industry - Challenges & Opportunities in 2008 and Beyond, joining distinguished faculty from Best Practices, Jazz Pharmaceuticals, and Scientific Advantage.
Dr. Fugh-Berman and Ms. Ryan joins top industry leaders in this field including Hon. Gene Green (D-TX), Member, Health Subcommittee - Energy & Commerce Committee, U. S. House of Representatives; Paul J. Savidge, VP, Global Labeling & Compliance, Bristol-Myers Squibb; Liliana A. Gil, Worldwide Director of Marketing Services & Hispanic Strategy Lead, Johnson & Johnson; and Ellen Shapiro, Director, Division of Communications, Center for Drug Evaluation and Research (CDER), FDA.
This year's agenda will review the latest developments - legislative and otherwise - from Capitol Hill to burgeoning competition to missed opportunities affecting Big Pharma's marketing, sales, and compliance efforts for market dominance.
For Conference Updates and Speaker Roster: http://www.iibig.com/P0802.
Copyright©2008 PR Newswire.
All rights reserved